DWM
SRPT icon

Doyle Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Doyle Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-50
Closed -$8K – 690
2019
Q2 		$8K Buy
+50
New +$6.08K ﹤0.01% 676
2019
Q1 		– Sell
-50
Closed -$5K – 674
2018
Q4 		$5K Buy
+50
New +$6.25K ﹤0.01% 728

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Doyle Wealth Management's SRPT Position: Q3 2019 in Review

Doyle Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 50 shares — an estimated $8K sold.

Doyle Wealth Management first reported a position in SRPT in Q4 2018 and held it in 2 quarters. The position peaked at $8K in Q2 2019. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Doyle Wealth Management reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Doyle Wealth Management sold 50 Sarepta Therapeutics shares in Q3 2019, an estimated $8K.
  • Doyle Wealth Management first reported a position in Sarepta Therapeutics in Q4 2018 and held it in 2 quarters.
  • Doyle Wealth Management's Sarepta Therapeutics position peaked at $8K in Q2 2019.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Doyle Wealth Management's 13F filing for Q3 2019, filed 5 Nov 2019.